PA
EVFM

Perceptive Advisors’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Perceptive Advisors’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-222
Closed -$180K – 195
2015
Q2 		$180K Buy
+222
New +$142K 0.01% 165

Other funds holding EVFM

CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Amici Capital New York $257M AUM 4.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Perceptive Advisors's EVFM Position: Q3 2015 in Review

Perceptive Advisors sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2015, closing a stake of 222 shares — an estimated $180K sold.

Perceptive Advisors first reported a position in EVFM in Q2 2015 and held it in 1 quarter. The position peaked at $180K in Q2 2015. 29 funds tracked by Wall St. Rank hold EVFM as of Q3 2015.

  • Perceptive Advisors reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
  • Perceptive Advisors sold 222 Evofem Biosciences, Inc. Common Stock shares in Q3 2015, an estimated $180K.
  • Perceptive Advisors first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2015 and held it in 1 quarter.
  • Perceptive Advisors's Evofem Biosciences, Inc. Common Stock position peaked at $180K in Q2 2015.
  • 29 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2015.

Based on Perceptive Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.